Abstract
The emergence of multidrug-resistant (MDR) and, more recently, of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis is a real threat to achieve tuberculosis (TB) control and elimination globally. More than 510,000 new cases of MDR-TB occur each year and XDR-TB cases are recognized in every setting where there has been the capacity to detect them, particularly in Eastern Europe. MDR- and XDR-TB control in Europe and the United States are heavily affected by what happens globally, as the majority of cases occurring in these countries originate in high TB-burden areas of the world. Scaling-up of culture- and drug susceptibility testing capacities and the expanded use of high-technology assays for rapid determination of resistance represent the prerequisites to achieve better control of MDR- and XDR-TB. Most cases with MDR- and XDR-TB in Europe and the United States can be treated successfully if well-designed regimens based on available second- and third-line anti-TB drugs are used and surgical options are carefully considered. Nevertheless, the development of new (more effective and less toxic) drugs to treat patients infected by MDR- and XDR-TB strains with or without active disease are urgently needed. Adherence to internationally agreed standards of care and control practices is imperative to achieve TB control.
| Original language | English |
|---|---|
| Pages (from-to) | 637-665 |
| Number of pages | 29 |
| Journal | Clinics in Chest Medicine |
| Volume | 30 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Dec 2009 |
Fingerprint
Keywords
- Epidemiology
- Europe
- MDR-TB
- Surveillance
- Tuberculosis control
- United States
- XDR-TB
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States : Epidemiology, Surveillance, and Control. / Migliori, Giovanni Battista; D' Arcy Richardson, Morgan; Sotgiu, Giovanni; Lange, Christoph.
In: Clinics in Chest Medicine, Vol. 30, No. 4, 12.2009, p. 637-665.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States
T2 - Epidemiology, Surveillance, and Control
AU - Migliori, Giovanni Battista
AU - D' Arcy Richardson, Morgan
AU - Sotgiu, Giovanni
AU - Lange, Christoph
PY - 2009/12
Y1 - 2009/12
N2 - The emergence of multidrug-resistant (MDR) and, more recently, of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis is a real threat to achieve tuberculosis (TB) control and elimination globally. More than 510,000 new cases of MDR-TB occur each year and XDR-TB cases are recognized in every setting where there has been the capacity to detect them, particularly in Eastern Europe. MDR- and XDR-TB control in Europe and the United States are heavily affected by what happens globally, as the majority of cases occurring in these countries originate in high TB-burden areas of the world. Scaling-up of culture- and drug susceptibility testing capacities and the expanded use of high-technology assays for rapid determination of resistance represent the prerequisites to achieve better control of MDR- and XDR-TB. Most cases with MDR- and XDR-TB in Europe and the United States can be treated successfully if well-designed regimens based on available second- and third-line anti-TB drugs are used and surgical options are carefully considered. Nevertheless, the development of new (more effective and less toxic) drugs to treat patients infected by MDR- and XDR-TB strains with or without active disease are urgently needed. Adherence to internationally agreed standards of care and control practices is imperative to achieve TB control.
AB - The emergence of multidrug-resistant (MDR) and, more recently, of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis is a real threat to achieve tuberculosis (TB) control and elimination globally. More than 510,000 new cases of MDR-TB occur each year and XDR-TB cases are recognized in every setting where there has been the capacity to detect them, particularly in Eastern Europe. MDR- and XDR-TB control in Europe and the United States are heavily affected by what happens globally, as the majority of cases occurring in these countries originate in high TB-burden areas of the world. Scaling-up of culture- and drug susceptibility testing capacities and the expanded use of high-technology assays for rapid determination of resistance represent the prerequisites to achieve better control of MDR- and XDR-TB. Most cases with MDR- and XDR-TB in Europe and the United States can be treated successfully if well-designed regimens based on available second- and third-line anti-TB drugs are used and surgical options are carefully considered. Nevertheless, the development of new (more effective and less toxic) drugs to treat patients infected by MDR- and XDR-TB strains with or without active disease are urgently needed. Adherence to internationally agreed standards of care and control practices is imperative to achieve TB control.
KW - Epidemiology
KW - Europe
KW - MDR-TB
KW - Surveillance
KW - Tuberculosis control
KW - United States
KW - XDR-TB
UR - http://www.scopus.com/inward/record.url?scp=71549149666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71549149666&partnerID=8YFLogxK
U2 - 10.1016/j.ccm.2009.08.015
DO - 10.1016/j.ccm.2009.08.015
M3 - Article
C2 - 19925959
AN - SCOPUS:71549149666
VL - 30
SP - 637
EP - 665
JO - Clinics in Chest Medicine
JF - Clinics in Chest Medicine
SN - 0272-5231
IS - 4
ER -